Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments

Teresa Battaglia, Elisa De Grandis, Marisol Mirabelli-Badenier, Luca Boeri, Guido Morcaldi, Paola Barabino, Chiara Intra, Francesca Naselli, Vito Pistoia, Edvige Veneselli, Massimo Conte

Research output: Contribution to journalArticle


We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). Treatment response was recorded on the basis of an international score at 0, 3, 6, 9 and 12 months. Despite the long disease duration and the numerous previously administered treatments, all patients underwent rapid and persistent neurological recovery following rituximab administration, thus suggesting a potential role of this drug even in pre-treated patients.

Original languageEnglish
Pages (from-to)192-195
Number of pages4
JournalEuropean Journal of Paediatric Neurology
Issue number2
Publication statusPublished - Mar 2012



  • Opsoclonus-myoclonus syndrome
  • Paraneoplastic syndromes
  • Rituximab
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this